United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020
Barnett B, Parker S, Weleff J. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. International Journal Of Drug Policy 2021, 99: 103473. PMID: 34624734, DOI: 10.1016/j.drugpo.2021.103473.Peer-Reviewed Original ResearchMeSH KeywordsHallucinogensHumansLysergic Acid DiethylamideN-Methyl-3,4-methylenedioxyamphetamineNational Institutes of Health (U.S.)PsilocybinUnited StatesConceptsNational Institutes of HealthNational Institutes of Health grantsPsychedelic-assisted therapyResearch funding bodiesClinical trialsPublic funder of biomedical researchMental health conditionsNational Institutes of Health fundingNational Institutes of Health RePORTERFunding bodiesUnited States National Institutes of HealthSchedule 1 drugFunder of biomedical researchInstitutes of HealthFunding clinical trialsNIH grant supportHealth conditionsPsychedelic renaissanceUnited KingdomGrant fundingGrant databasesStudy periodPublic funders